US4906467A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Novel, long-duration treatment for glaucoma
Assignee: New York Medical College
•
Filing: 1988-03-24
•
Granted: 1990-03-06
•
Expires: 2008-03-24
Abstract
Abstract The present invention relates to a method of and composition for reducing intraocular pressure. The method comprises administering to a patient requiring such reduction of intraocular pressure a therapeutically effective amount of 12(R)-hydroxy-eicosa-5,8,10,14-tetraenoic acid (12(R)-HETE). The method of the present invention is particularly useful in treatment of all types of glaucoma. The method is also useful in lowering intraocular pressure in preparation for eye surgery, particularly for the removal of cataracts.
Inventors
- 👤 Michal L. Schwartzman
- 👤 Michael W. Dunn
- 👤 Jaime L. Masferrer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 06:40
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/20
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
27 words
A method for reducing intraocular pressure, which comprises administering to the eye a therapeutically effective amount of 12(R)-hydroxy-eicosa-5,8,10,14-tetraenoic acid or a pharmaceutically acceptable salt or ester thereof.
Claim 2
Independent Claim
27 words
A method for reducing intraocular pressure, which comprises administering to the eye a therapeutically effective amount of 12(R)-hydroxy-eicosa-5,8,10,14-tetraenoic acid or a pharmaceutically acceptable salt or ester thereof.
Claim 3
Dependent Claim
24 words
The method according to claim 1 wherein the 12(R)-hydroxy-eicosa-5,8,10,14-tetraneoic acid is dissolved or suspended in a vehicle suitable for topical administration to the eye.
Claim 4
Dependent Claim
36 words
The method according to claim 2 wherein said vehicle is selected from the group consisting of methylcellulose, balanced salt solution, PVP, polyvinyl alcohol, hydroxyethyl cellulose, hydroxy-propylcellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, boric acid, mineral oil, and povidone.
Claim 5
Dependent Claim
16 words
The method according to claim 1 wherein the effective amount of 12(R)-hydroxy-eicosa-5,8,10,14-tetraenoic acid is 0.1-1 μg/eye.
Claim 6
Dependent Claim
16 words
The method according to claim 1 wherein the effective amount of 12(R)-hydroxy-eicosa-5,8,10,14-tetraenoic acid is 0.2-0.5 μg/eye.
Claim 7
Dependent Claim
33 words
A composition for the treatment of glucoma or ocular hypertension, consisting essentially of a therapeutically effective amount of 12(R)-hydroxy-eicosa-5,8,10,14-tetraenoic acid or a pharmaceutically acceptable salt or ester thereof and a pharmaceutically acceptable vehicle.
Claim 8
Dependent Claim
33 words
A composition for the treatment of glucoma or ocular hypertension, consisting essentially of a therapeutically effective amount of 12(R)-hydroxy-eicosa-5,8,10,14-tetraenoic acid or a pharmaceutically acceptable salt or ester thereof and a pharmaceutically acceptable vehicle.
Claim 9
Dependent Claim
18 words
A composition in accordance with claim 6 wherein said vehicle is suitable for topical administration to the eye.
Claim 10
Dependent Claim
37 words
A composition in accordance with claim 6 wherein said vehicle is selected from the group consisting of methylcellulose, balanced salt solution, PVP, polyvinyl alcohol, hydroxyethyl cellulose, hydroxy-propylcellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, boric acid, mineral oil, and povidone.
Claim 11
Dependent Claim
15 words
A composition according to claim 6 wherein the concentration of 12(R)-hydroxy-eicosa-5,8,10,14-tetraenoic acid is 2-20 μg/ml.
Claim 12
Independent Claim
29 words
A method for treating glaucoma or ocular hypertension which comprises administering to the eye a therapeutically effective amount of 12(R)-hydroxy-eicosa-5,8,10,14-tetraenoic acid or a pharmaceutically acceptable salt or ester thereof.
Claim 13
Independent Claim
29 words
A method for treating glaucoma or ocular hypertension which comprises administering to the eye a therapeutically effective amount of 12(R)-hydroxy-eicosa-5,8,10,14-tetraenoic acid or a pharmaceutically acceptable salt or ester thereof.
Claim 14
Dependent Claim
21 words
The method according to claim 1, wherein the therapeutically effective amount of 12(R)-hydroxy-eicosa-5,8,10,14-tetraenoic acid is from 0.1 μg/eye to 1.0 μg/eye.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-03-05 | 1993-09-04 | 1994-03-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-03-05 | 1997-09-04 | 1998-03-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-03-05 | 2001-09-04 | 2002-03-06 | $7700.00 | Window Closed / Lapsed |